目錄肽產(chǎn)品
GLUC-011A
Glucagon-Like Peptide II, human
His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg
His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg
Size：0.5
P1(RMB)：582
MW：3922.4
One letter sequence：HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
Molecular Formula：C171H266N48O56S1
Description：Intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently GLP-2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
Literature Reference：D.J. Drucker, Trends Endocrinol. Metab., 10, 153 (1999); \nD.J. Drucker et al., J. Parenter. Enteral Nutr., 23, 598 (1999)
Cas：[99120-49-7]
P1(RMB)：582
MW：3922.4
One letter sequence：HADGSFSDEMNTILDNLAARDFINWLIQTKITDR
Molecular Formula：C171H266N48O56S1
Description：Intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently GLP-2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
Literature Reference：D.J. Drucker, Trends Endocrinol. Metab., 10, 153 (1999); \nD.J. Drucker et al., J. Parenter. Enteral Nutr., 23, 598 (1999)
Cas：[99120-49-7]
-
ADD杭州市錢塘區(qū)12號大街69號
-
TEL0571-86737011
-
E-mail
Copyright ? 2024 中肽生化有限公司 All Rights Reserved.
浙ICP備05051877號-1
業(yè)務(wù)咨詢和客戶服務(wù)
企業(yè)微信公眾號
